Search | Clinical Trials Finder

Conditions: COVID-19
Interventions: Remdesivir, Standard of Care; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 12 Years and older
Enrollment: 1,113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 106
States / cities: Anaheim, California • Berkeley, California • Burlingame, California + 76 more

Conditions: Advanced Cancer
Interventions: RBS2418, Pembrolizumab, Other approved anti-cancer therapy; Drug
Lead sponsor: Riboscience, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 14
States / cities: Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 11 more

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Loncastuximab, Roflumilast, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Ductal Carcinoma in Situ, Lobular Carcinoma in Situ
Interventions: CAN1012; Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
Interventions: Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W); Drug
Lead sponsor: QuantumLeap Healthcare Collaborative; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2031
U.S. locations: 42
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more

Conditions: Squamous Cell Carcinoma of Head and Neck
Interventions: Amivantamab, Pembrolizumab, Carboplatin, 5-Flurouracil, Cisplatin; Biological · Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 47
States / cities: Chandler, Arizona • Tucson, Arizona • Fullerton, California + 41 more

Conditions: Oropharyngeal Squamous Cell Carcinoma
Interventions: CUE-101; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Glioblastoma Multiforme
Interventions: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Standard Fractionated Radiation therapy (RT), Bevacizumab, TTField, Carmustine; Drug · Radiation · Device
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: Chronic Hepatitis B
Interventions: standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI); Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 71 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 17
States / cities: Beverly Hills, California • Coronado, California • Los Angeles, California + 10 more

Conditions: Extensive Stage-small Cell Lung Cancer
Interventions: Ifinatamab deruxtecan, Atezolizumab, Carboplatin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more

Conditions: Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
Interventions: Visugromab, Matching placebo for visugromab, Pembrolizumab 200 mg Q3W, Pemetrexed 500 mg/m^2, Carboplatin AUC 5; Biological · Drug
Lead sponsor: CatalYm GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 7
States / cities: Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 4 more

Conditions: Solid Tumors
Interventions: mRNA-4157, Pembrolizumab, SoC Treatment; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more

Conditions: Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Interventions: Telisotuzumab Adizutecan, Budigalimab, Fluorouracil, Leucovorin, Oxaliplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 8
States / cities: Duarte, California • Irvine, California • Santa Monica, California + 5 more

Conditions: Prostate Cancer, Advanced Cancer
Interventions: Radium-223, 177Lu-DOTATATE, 177Lu-PSMA-617; Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Standard of Care (SOC) Oral ART, Oral RPV, Oral CAB, RPV-LA Loading Dose, CAB-LA Loading Dose, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 32
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more

Conditions: Pancreatic Cancer
Interventions: multiTAA specific T cells; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS); Drug · Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2038
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: AL Amyloidosis
Interventions: CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Stanford, California • Detroit, Michigan • Cleveland, Ohio

Conditions: Glioblastoma Multiforme
Interventions: VBI-1901, Carmustine, Lomustine; Biological · Drug
Lead sponsor: VBI Vaccines Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 12
States / cities: Irvine, California • La Jolla, California • Los Angeles, California + 8 more

Conditions: Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Interventions: MEDI-573 (1 of 3 doses), Sorafenib; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Oxnard, California • Golden Springs, Colorado • Las Vegas, Nevada

Conditions: Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
Interventions: Behavioral Intervention, Beta-Adrenergic Antagonist, Propranolol, Quality-of-Life Assessment, Questionnaire Administration, Resistance Training, Short-Term Fasting; Behavioral · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cannabis Use Disorder, Stimulant Use Disorder, Opioid Use Disorder, Tobacco Use Disorder, Alcohol Use Disorder, Sedative, Hypnotic, or Anxiolytic Use Disorders
Interventions: Emotional Brain Training, Standard addiction counseling and medical therapy; Behavioral · Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Bernardino, California

Conditions: Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: 3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy; Radiation · Drug · Procedure + 1 more
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older · Male only
Enrollment: 804 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2032
U.S. locations: 341
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more

Conditions: Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer, Oesophageal Adenocarcinoma
Interventions: THOR-707, Pembrolizumab, Cetuximab; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Duarte, California • Orlando, Florida • Seattle, Washington

Search by objective public record fields.

Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

CAN1012 in Pre-Malignant DCIS and LCIS

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

Emotional Brain Training for Addiction Medicine Treatment - A Pilot Study

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)